CCBIO Seminar - Øystein Rekdal
Welcome to a CCBIO Seminar with speaker Øystein Rekdal from Lytix Biopharma AS and The Arctic University of Norway, Tromsø. Title: "From Bench to Bedside with a first in class oncolytic peptide".
Speaker: Øystein Rekdal, PhD, from Lytix Biopharma AS and The Arctic University of Norway, Tromsø
Title: From Bench to Bedside with a first in class oncolytic peptide
The oncolytic peptide LTX-315 has been designed de novo based on structureactivity relationship studies of host defense peptides. This peptide has the ability to kill human cancer cells and induce a specific anticancer immune response when injected locally into tumors established in immunocompetent mice. The oncolytic effect of LTX-315 involves perturbation of the plasma membrane and the mitochondria with subsequent release of danger-associated molecular pattern molecules and tumor antigens which highlights the ability of LTX-315 to induce complete regression and protective immune responses. Systemic efficacy can be enhanced in vivo by combination with several other types of cancer therapies.Clinical safety has been demonstrated as a single agent administered intratumorally in a phase I study. Best overall response seen in cancer patients was stable disease (SD). However, in several patients a marked tumor regression was observed in distant non-injected lesions. LTX-315 monotherapy resulted in increased number of cytotoxic CD8+ T cells in the majority of treated lesions. T cell receptor (TCR) sequencing revealed a systemic clonal expansion of T cells after LTX-315 treatment. The clinical results generated demonstrate the potential of LTX-315 as a primer of tumor specific T cells, making it ideal for combination with other immunotherapies.
Chairperson: Bjørn Tore Gjertsen
All interested researchers, students and others are welcome, both to the seminar and the following pizza get-together!